var data={"title":"Isoniazid hepatotoxicity","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Isoniazid hepatotoxicity</div><dl id=\"topicContributors\"><dt><span> </span>Authors:</dt><dd><a href=\"https://www.uptodate.com/contents/isoniazid-hepatotoxicity/contributors\" class=\"contributor contributor_credentials\">Anne M Larson, MD, FACP, FAASLD, AGAF</a></dd><dd><a href=\"https://www.uptodate.com/contents/isoniazid-hepatotoxicity/contributors\" class=\"contributor contributor_credentials\">Amy L Graziani, PharmD</a></dd><dt><span> </span>Section Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/isoniazid-hepatotoxicity/contributors\" class=\"contributor contributor_credentials\">C Fordham von Reyn, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/isoniazid-hepatotoxicity/contributors\" class=\"contributor contributor_credentials\">Elinor L Baron, MD, DTMH</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/isoniazid-hepatotoxicity/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Feb 09, 2017.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H1\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=isoniazid-drug-information\" class=\"drug drug_general\">Isoniazid</a> (INH; isonicotinylhydrazide or isonicotinic acid hydrazine) is a synthetic antibiotic that is potently bactericidal against replicating <em>Mycobacterium tuberculosis</em>. INH has since been associated with two syndromes of hepatotoxicity: mild INH hepatotoxicity and INH hepatitis [<a href=\"https://www.uptodate.com/contents/isoniazid-hepatotoxicity/abstract/1-3\" class=\"abstract_t\">1-3</a>].</p><p>Issues related to INH hepatotoxicity will be reviewed here. The clinical use of INH is discussed separately. (See <a href=\"topic.htm?path=treatment-of-latent-tuberculosis-infection-in-hiv-uninfected-adults\" class=\"medical medical_review\">&quot;Treatment of latent tuberculosis infection in HIV-uninfected adults&quot;</a> and <a href=\"topic.htm?path=treatment-of-drug-susceptible-pulmonary-tuberculosis-in-hiv-uninfected-adults\" class=\"medical medical_review\">&quot;Treatment of drug-susceptible pulmonary tuberculosis in HIV-uninfected adults&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H2\"><span class=\"h1\">MILD INH HEPATOTOXICITY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Mild <a href=\"topic.htm?path=isoniazid-drug-information\" class=\"drug drug_general\">isoniazid</a> (INH) hepatotoxicity refers to hepatic injury that is typically subclinical and evidenced only by mildly elevated serum aminotransferases (usually &lt;100 international <span class=\"nowrap\">units/L)</span> [<a href=\"https://www.uptodate.com/contents/isoniazid-hepatotoxicity/abstract/4-6\" class=\"abstract_t\">4-6</a>]. It occurs in up to 20 percent of patients treated with isoniazid [<a href=\"https://www.uptodate.com/contents/isoniazid-hepatotoxicity/abstract/7-11\" class=\"abstract_t\">7-11</a>].</p><p>Adults are more likely to be affected than children; men and women appear to be equally vulnerable. There is no relationship to race or the rate of hepatic acetylation of the drug.</p><p>Most cases are self-limited; in general, INH therapy can be continued with careful monitoring in the absence of dose adjustment. Typically aminotransferase levels return to normal within several weeks after discontinuation of INH [<a href=\"https://www.uptodate.com/contents/isoniazid-hepatotoxicity/abstract/12,13\" class=\"abstract_t\">12,13</a>].</p><p class=\"headingAnchor\" id=\"H3\"><span class=\"h1\">INH HEPATITIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=isoniazid-drug-information\" class=\"drug drug_general\">Isoniazid</a> (INH) hepatitis is a more serious liver injury syndrome than mild INH hepatotoxicity; it is usually symptomatic and may be fatal [<a href=\"https://www.uptodate.com/contents/isoniazid-hepatotoxicity/abstract/14,15\" class=\"abstract_t\">14,15</a>]. It is an idiosyncratic reaction that is not clearly related to dose or duration of therapy.</p><p class=\"headingAnchor\" id=\"H4\"><span class=\"h2\">Prevalence and risk factors</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The risk of INH hepatitis associated with <a href=\"topic.htm?path=isoniazid-drug-information\" class=\"drug drug_general\">isoniazid</a> therapy for treatment of latent tuberculosis is 0.5 to 1.0 percent; INH hepatitis is fatal in 0.05 to 0.1 percent of cases [<a href=\"https://www.uptodate.com/contents/isoniazid-hepatotoxicity/abstract/6,16-21\" class=\"abstract_t\">6,16-21</a>].</p><p>Risk factors for the development of hepatotoxicity include [<a href=\"https://www.uptodate.com/contents/isoniazid-hepatotoxicity/abstract/6,17,22-31\" class=\"abstract_t\">6,17,22-31</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Increased age [<a href=\"https://www.uptodate.com/contents/isoniazid-hepatotoxicity/abstract/17,32-34\" class=\"abstract_t\">17,32-34</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Regular alcohol intake [<a href=\"https://www.uptodate.com/contents/isoniazid-hepatotoxicity/abstract/17,23\" class=\"abstract_t\">17,23</a>]. It is possible that the use of alcohol may increase the risk of hepatotoxicity. One study noted development of hepatitis in 2.6 percent of patients treated with <a href=\"topic.htm?path=isoniazid-drug-information\" class=\"drug drug_general\">isoniazid</a> who drank alcohol daily [<a href=\"https://www.uptodate.com/contents/isoniazid-hepatotoxicity/abstract/35\" class=\"abstract_t\">35</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Concurrent use of medications that induce CYP (P450) oxidative enzymes (<a href=\"image.htm?imageKey=CARD%2F76992\" class=\"graphic graphic_table graphicRef76992 \">table 1</a>) <span class=\"nowrap\">and/or</span> are themselves hepatotoxic.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Previous INH intolerance (eg, headaches, dizziness, nausea). Rechallenge with INH may result in recurrence of hepatotoxicity; however, some studies have shown that up to 80 percent of persons may be able to tolerate reintroduction of the drug [<a href=\"https://www.uptodate.com/contents/isoniazid-hepatotoxicity/abstract/36,37\" class=\"abstract_t\">36,37</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Prior or concurrent liver disease, such as chronic viral hepatitis [<a href=\"https://www.uptodate.com/contents/isoniazid-hepatotoxicity/abstract/38-41\" class=\"abstract_t\">38-41</a>]. In one study of Vietnamese patients with hepatitis B treated with INH for latent tuberculosis infection, patients with HBeAg positivity were more likely to develop severe INH toxicity than patients who were HBeAg negative [<a href=\"https://www.uptodate.com/contents/isoniazid-hepatotoxicity/abstract/39\" class=\"abstract_t\">39</a>]. However, other studies have not observed an association between chronic viral hepatitis and risk for INH hepatotoxicity [<a href=\"https://www.uptodate.com/contents/isoniazid-hepatotoxicity/abstract/42\" class=\"abstract_t\">42</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>History of peripheral neuropathy or presence of risk factors for peripheral neuropathy (eg, due to diabetes mellitus or alcoholism).</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Pregnancy and the immediate postpartum period.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Injection drug use.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Female gender (particularly if nonwhite) [<a href=\"https://www.uptodate.com/contents/isoniazid-hepatotoxicity/abstract/33,43,44\" class=\"abstract_t\">33,43,44</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Genetic predisposition (as in the case of rapid acetylators) [<a href=\"https://www.uptodate.com/contents/isoniazid-hepatotoxicity/abstract/45-48\" class=\"abstract_t\">45-48</a>]. (See <a href=\"#H11\" class=\"local\">'Mechanism of hepatotoxicity'</a> below.)</p><p/><p class=\"headingAnchor\" id=\"H5\"><span class=\"h2\">Clinical manifestations</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Clinical manifestations of INH hepatitis typically occur within the first two to three months after initiation of therapy; they can occur as late as 14 months after initiation of therapy [<a href=\"https://www.uptodate.com/contents/isoniazid-hepatotoxicity/abstract/6,13,17,22\" class=\"abstract_t\">6,13,17,22</a>].</p><p>Clinical manifestations include fatigue, malaise, anorexia, <span class=\"nowrap\">and/or</span> nausea, with or without vomiting. Approximately one-third of patients have generalized flu-like symptoms, and some have right upper quadrant pain. Liver injury is typically hepatocellular; however, jaundice is a presenting feature in approximately 10 percent of cases and manifests days to weeks after onset of the above symptoms [<a href=\"https://www.uptodate.com/contents/isoniazid-hepatotoxicity/abstract/22,49\" class=\"abstract_t\">22,49</a>].</p><p>INH hepatitis may be associated with the development of hepatocellular necrosis and acute liver failure in up to 1 to 3 percent of cases; clinical manifestations may include ascites, edema, and encephalopathy [<a href=\"https://www.uptodate.com/contents/isoniazid-hepatotoxicity/abstract/6,17,33\" class=\"abstract_t\">6,17,33</a>]. The physical examination is largely nonspecific. Jaundice and abdominal pain may be present. Fever, rash, lymphadenopathy, and hepatomegaly are uncommon.</p><p>Laboratory evaluation characteristically demonstrates elevated aminotransferases (&gt;10 times the upper limit of normal [ULN]) and variable elevations in alkaline phosphatase (usually &lt;2 times ULN), bilirubin, and prothrombin time [<a href=\"https://www.uptodate.com/contents/isoniazid-hepatotoxicity/abstract/33\" class=\"abstract_t\">33</a>].</p><p>Histologically, liver injury is predominantly hepatocellular in nature and ranges from focal mononuclear cell infiltrate to diffuse massive necrosis [<a href=\"https://www.uptodate.com/contents/isoniazid-hepatotoxicity/abstract/13,49,50\" class=\"abstract_t\">13,49,50</a>].</p><p class=\"headingAnchor\" id=\"H6\"><span class=\"h2\">Diagnosis</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The diagnosis of INH hepatitis should be suspected in patients taking <a href=\"topic.htm?path=isoniazid-drug-information\" class=\"drug drug_general\">isoniazid</a> who develop fatigue, malaise, anorexia, nausea, <span class=\"nowrap\">and/or</span> vomiting in association with elevated serum aminotransferases. The diagnosis is established clinically, based on clinical manifestations and exclusion of other causes; the diagnosis is supported by resolution of elevated aminotransferases within several weeks after discontinuation of therapy [<a href=\"https://www.uptodate.com/contents/isoniazid-hepatotoxicity/abstract/3\" class=\"abstract_t\">3</a>].</p><p>There is overlap in the pattern of liver injury caused by <a href=\"topic.htm?path=isoniazid-drug-information\" class=\"drug drug_general\">isoniazid</a> and other antituberculous agents including <a href=\"topic.htm?path=rifampin-rifampicin-drug-information\" class=\"drug drug_general\">rifampin</a> and <a href=\"topic.htm?path=pyrazinamide-drug-information\" class=\"drug drug_general\">pyrazinamide</a>; all individually or in combination may contribute to hepatotoxicity.</p><p>Clinical evaluation of patients with suspected INH hepatitis should include clinical history regarding alcohol use and exposure to other potential hepatotoxins. Laboratory evaluation should include testing for viral hepatitis and autoimmune hepatitis. (See <a href=\"#H12496295\" class=\"local\">'Differential diagnosis'</a> below.)</p><p>Additional issues related to diagnostic evaluation of drug-induced liver injury are discussed separately. (See <a href=\"topic.htm?path=drug-induced-liver-injury#H28\" class=\"medical medical_review\">&quot;Drug-induced liver injury&quot;, section on 'Diagnosis'</a>.)</p><p class=\"headingAnchor\" id=\"H12496295\"><span class=\"h2\">Differential diagnosis</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The differential diagnosis of INH hepatitis includes other causes of elevated aminotransferases (see <a href=\"topic.htm?path=approach-to-the-patient-with-abnormal-liver-biochemical-and-function-tests#H19404948\" class=\"medical medical_review\">&quot;Approach to the patient with abnormal liver biochemical and function tests&quot;, section on 'Elevated serum aminotransferases'</a>):</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Viral hepatitis &ndash; Viral hepatitis can occur as a result of infection due to hepatitis A, B, C, D, E, Epstein-Barr virus, cytomegalovirus, HIV, or other viral infections. The clinical manifestations include fatigue, malaise, anorexia, nausea, <span class=\"nowrap\">and/or</span> vomiting. The diagnosis is established via serology. (See related topics).</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Drug-induced liver injury &ndash; Drug-induced liver injury associated with medications or herbal therapies may present with mild, asymptomatic liver test abnormalities, cholestasis with pruritus, acute jaundice, or acute liver failure. The diagnosis is established based clinically. (See <a href=\"topic.htm?path=drug-induced-liver-injury\" class=\"medical medical_review\">&quot;Drug-induced liver injury&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Autoimmune hepatitis &ndash; Clinical manifestations of autoimmune hepatitis include fatigue, anorexia, nausea, abdominal pain, and itching. <a href=\"topic.htm?path=isoniazid-drug-information\" class=\"drug drug_general\">Isoniazid</a> can induce development antinuclear antibodies, even without hepatotoxicity. In the setting of INH hepatitis, autoantibody titers are generally low and hyperglobulinemia is not seen. The diagnosis of autoimmune hepatitis is based upon characteristic serologic and histologic findings. (See <a href=\"topic.htm?path=autoimmune-hepatitis-clinical-manifestations-and-diagnosis\" class=\"medical medical_review\">&quot;Autoimmune hepatitis: Clinical manifestations and diagnosis&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Ischemic injury &ndash; Ischemic hepatitis refers to diffuse hepatic injury resulting from acute hypoperfusion. Most patients have no symptoms referable to the liver but have marked elevation of the serum aminotransferase levels (exceeding 1000 international <span class=\"nowrap\">units/L</span> or 50 times the upper limit of normal) after an episode of hypotension. (See <a href=\"topic.htm?path=ischemic-hepatitis-hepatic-infarction-and-ischemic-cholangiopathy\" class=\"medical medical_review\">&quot;Ischemic hepatitis, hepatic infarction, and ischemic cholangiopathy&quot;</a>.)</p><p/><p class=\"headingAnchor\" id=\"H7\"><span class=\"h2\">Management</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Management of INH hepatitis consists of timely discontinuation of INH and other potential hepatotoxins [<a href=\"https://www.uptodate.com/contents/isoniazid-hepatotoxicity/abstract/6\" class=\"abstract_t\">6</a>]. In severe cases, liver transplantation may be required [<a href=\"https://www.uptodate.com/contents/isoniazid-hepatotoxicity/abstract/17,51\" class=\"abstract_t\">17,51</a>].</p><p>In general, hepatitis attributed to antituberculous drugs should prompt discontinuation of all hepatotoxic drugs if the serum bilirubin is &ge;3 <span class=\"nowrap\">mg/dL</span> or serum transaminases are more than five times the upper limit of normal (<a href=\"image.htm?imageKey=ID%2F109447\" class=\"graphic graphic_algorithm graphicRef109447 \">algorithm 1</a>) [<a href=\"https://www.uptodate.com/contents/isoniazid-hepatotoxicity/abstract/1,3\" class=\"abstract_t\">1,3</a>].</p><p>Once liver function tests return to baseline (or fall to less than twice normal), potentially hepatotoxic drugs can be restarted one at a time with careful monitoring between resumption of each agent (<a href=\"image.htm?imageKey=ID%2F109447\" class=\"graphic graphic_algorithm graphicRef109447 \">algorithm 1</a>). (See <a href=\"topic.htm?path=treatment-of-drug-susceptible-pulmonary-tuberculosis-in-hiv-uninfected-adults#H3158717734\" class=\"medical medical_review\">&quot;Treatment of drug-susceptible pulmonary tuberculosis in HIV-uninfected adults&quot;, section on 'Hepatotoxicity'</a>.)</p><p>The approach to regimen adjustment for drug intolerance is discussed separately. (See <a href=\"topic.htm?path=treatment-of-drug-susceptible-pulmonary-tuberculosis-in-hiv-uninfected-adults#H9\" class=\"medical medical_review\">&quot;Treatment of drug-susceptible pulmonary tuberculosis in HIV-uninfected adults&quot;, section on 'Regimen adjustments for drug intolerance'</a> and <a href=\"topic.htm?path=treatment-of-latent-tuberculosis-infection-in-hiv-uninfected-adults#H9\" class=\"medical medical_review\">&quot;Treatment of latent tuberculosis infection in HIV-uninfected adults&quot;, section on 'Monitoring'</a>.)</p><p class=\"headingAnchor\" id=\"H883838081\"><span class=\"h2\">Prevention</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Use of INH should be limited to appropriate clinical circumstances, and patients should be educated about the signs and symptoms of hepatic toxicity [<a href=\"https://www.uptodate.com/contents/isoniazid-hepatotoxicity/abstract/3,17,52\" class=\"abstract_t\">3,17,52</a>].</p><p>Issues related to clinical and laboratory monitoring for patients on <a href=\"topic.htm?path=isoniazid-drug-information\" class=\"drug drug_general\">isoniazid</a> for treatment of latent tuberculosis infection are discussed separately. (See <a href=\"topic.htm?path=treatment-of-latent-tuberculosis-infection-in-hiv-uninfected-adults#H9\" class=\"medical medical_review\">&quot;Treatment of latent tuberculosis infection in HIV-uninfected adults&quot;, section on 'Monitoring'</a> and <a href=\"topic.htm?path=treatment-of-latent-tuberculosis-infection-in-hiv-infected-adults#H7712614\" class=\"medical medical_review\">&quot;Treatment of latent tuberculosis infection in HIV-infected adults&quot;, section on 'Patient monitoring'</a>.)</p><p>Issues related to clinical and laboratory monitoring for patients on <a href=\"topic.htm?path=isoniazid-drug-information\" class=\"drug drug_general\">isoniazid</a> and other antituberculous drugs for treatment of active tuberculosis infection are discussed separately. (See <a href=\"topic.htm?path=antituberculous-drugs-an-overview#H2636671244\" class=\"medical medical_review\">&quot;Antituberculous drugs: An overview&quot;, section on 'Clinical and laboratory monitoring for adverse effects'</a>.)</p><p class=\"headingAnchor\" id=\"H10\"><span class=\"h2\">Prognosis</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The overall case-fatality rate in patients who develop clinically apparent hepatitis is approximately 10 percent [<a href=\"https://www.uptodate.com/contents/isoniazid-hepatotoxicity/abstract/22\" class=\"abstract_t\">22</a>]. Older adult patients or those who present with INH hepatitis after taking the drug for more than two months have a worse prognosis [<a href=\"https://www.uptodate.com/contents/isoniazid-hepatotoxicity/abstract/5,22,53,54\" class=\"abstract_t\">5,22,53,54</a>]. Some studies have found a higher case-fatality rate among African-American patients than other patients, as well as a higher case-fatality rate among African-American women than African-American men [<a href=\"https://www.uptodate.com/contents/isoniazid-hepatotoxicity/abstract/22,29,55-57\" class=\"abstract_t\">22,29,55-57</a>].</p><p class=\"headingAnchor\" id=\"H11\"><span class=\"h1\">MECHANISM OF HEPATOTOXICITY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The mechanism of <a href=\"topic.htm?path=isoniazid-drug-information\" class=\"drug drug_general\">isoniazid</a> (INH) hepatotoxicity is not completely understood [<a href=\"https://www.uptodate.com/contents/isoniazid-hepatotoxicity/abstract/58\" class=\"abstract_t\">58</a>]. Toxicity is likely associated with metabolism of the drug [<a href=\"https://www.uptodate.com/contents/isoniazid-hepatotoxicity/abstract/22,58-60\" class=\"abstract_t\">22,58-60</a>]. Alternatively, liver injury may occur via induction of an immune response that causes liver injury [<a href=\"https://www.uptodate.com/contents/isoniazid-hepatotoxicity/abstract/61\" class=\"abstract_t\">61</a>].</p><p>INH is rapidly absorbed from the gastrointestinal tract and diffuses into all body tissues [<a href=\"https://www.uptodate.com/contents/isoniazid-hepatotoxicity/abstract/62\" class=\"abstract_t\">62</a>]. The plasma concentration reaches its peak approximately one to three hours after ingestion of the medication [<a href=\"https://www.uptodate.com/contents/isoniazid-hepatotoxicity/abstract/58\" class=\"abstract_t\">58</a>]. Hepatic metabolism of INH creates numerous metabolites including isonicotinic acid (INA), hydrazine (HZ), ammonia, N1-acetyl-N2-isonicotinylhydrazide (AcINH or acetylINH), monoacetylhydrazine (AcHZ), diacetylhydrazine (DiAcHZ), and oxidizing free radicals [<a href=\"https://www.uptodate.com/contents/isoniazid-hepatotoxicity/abstract/63\" class=\"abstract_t\">63</a>]. These compounds are formed via three predominant reactions [<a href=\"https://www.uptodate.com/contents/isoniazid-hepatotoxicity/abstract/64\" class=\"abstract_t\">64</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Acyl amidase hydrolysis &ndash; Forming INA and HZ</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Cytochrome P450 oxidation &ndash; Forming HZ, ammonia, and free radicals</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>N-acetyltransferase 2 (NAT2) activity &ndash; Forming AcINH, AcHZ, and DiAcHZ</p><p/><p>Hydrazine, AcHZ, and toxic free radicals are the drug metabolites that have been most consistently implicated in the pathogenesis of INH hepatitis [<a href=\"https://www.uptodate.com/contents/isoniazid-hepatotoxicity/abstract/65,66\" class=\"abstract_t\">65,66</a>]. INH is first acetylated in the liver via NAT2 to form the inactive compound AcINH, which is then hydrolyzed to form AcHZ and INA [<a href=\"https://www.uptodate.com/contents/isoniazid-hepatotoxicity/abstract/63\" class=\"abstract_t\">63</a>]. Acetylhydrazine is usually further acetylated to the nontoxic derivative diacetylhydrazine and excreted in the urine; it is also oxidized into ammonia by the liver (muscle, kidney, and brain also contribute) [<a href=\"https://www.uptodate.com/contents/isoniazid-hepatotoxicity/abstract/63\" class=\"abstract_t\">63</a>]. In addition, acetylhydrazine can be oxidized by the cytochrome P450 pathway to form toxic reactive acetyl free radicals that can form covalent bonds with liver cell macromolecules, interfering with their function and leading to hepatocellular necrosis and cell death [<a href=\"https://www.uptodate.com/contents/isoniazid-hepatotoxicity/abstract/5,7,45,59,65,67-69\" class=\"abstract_t\">5,7,45,59,65,67-69</a>]. Cytochrome isoforms 2E1, 2B1, and <span class=\"nowrap\">1A1/A2</span> have been implicated in this process [<a href=\"https://www.uptodate.com/contents/isoniazid-hepatotoxicity/abstract/70-72\" class=\"abstract_t\">70-72</a>].</p><p>NAT2 is the primary enzyme involved in the metabolism of INH, and deficiency of this enzyme has been associated with INH hepatotoxicity. The mechanism by which the NAT2 deficiency may cause hepatotoxicity is not known [<a href=\"https://www.uptodate.com/contents/isoniazid-hepatotoxicity/abstract/58\" class=\"abstract_t\">58</a>]. NAT2 is highly polymorphic, and genetic polymorphisms are associated with trimodal pharmacokinetics of INH: slow, intermediate, and fast acetylation [<a href=\"https://www.uptodate.com/contents/isoniazid-hepatotoxicity/abstract/73-77\" class=\"abstract_t\">73-77</a>]. Data on the association between acetylator phenotype and risk of INH hepatotoxicity remain conflicting [<a href=\"https://www.uptodate.com/contents/isoniazid-hepatotoxicity/abstract/8,25,27,32,53,64,68,78-87\" class=\"abstract_t\">8,25,27,32,53,64,68,78-87</a>]. In theory, rapid acetylation of AcHZ should reduce the formation of toxic acetylhydrazine oxidative metabolites [<a href=\"https://www.uptodate.com/contents/isoniazid-hepatotoxicity/abstract/45\" class=\"abstract_t\">45</a>].</p><p>Subsequent studies have demonstrated a higher rate of toxicity in slow acetylators, who have a higher concentration of AcHZ [<a href=\"https://www.uptodate.com/contents/isoniazid-hepatotoxicity/abstract/45-47,77,82,88,89\" class=\"abstract_t\">45-47,77,82,88,89</a>]. The AcHZ is then diverted into an alternate CYP pathway, which results in the development of hepatotoxic metabolites. Data that show a higher risk of hepatitis when INH is combined with <a href=\"topic.htm?path=rifampin-rifampicin-drug-information\" class=\"drug drug_general\">rifampin</a> and other CYP inducers support this theory [<a href=\"https://www.uptodate.com/contents/isoniazid-hepatotoxicity/abstract/80\" class=\"abstract_t\">80</a>]. In one study, for example, N-acetyltransferase (NAT2) and CYP2E1 testing was performed in 89 patients receiving INH for treatment of latent tuberculosis [<a href=\"https://www.uptodate.com/contents/isoniazid-hepatotoxicity/abstract/72\" class=\"abstract_t\">72</a>]. NAT2 testing was not predictive of hepatotoxicity, but the CYP2E1 <span class=\"nowrap\">*1a/*1a</span> genotype (but not CYP2E1 overall) significantly correlated with the development of elevated liver enzymes. Other data suggest that individuals carrying the CYP2E1 <span class=\"nowrap\">c1/c1</span> genotype are at greater risk for hepatotoxicity [<a href=\"https://www.uptodate.com/contents/isoniazid-hepatotoxicity/abstract/83\" class=\"abstract_t\">83</a>]. In a Chinese population, this genotype carried up to a 3.9-fold increased probability of hepatotoxicity in rapid acetylators and a 7.4-fold increased probability of hepatotoxicity in slow acetylators [<a href=\"https://www.uptodate.com/contents/isoniazid-hepatotoxicity/abstract/83\" class=\"abstract_t\">83</a>]. INH may also promote the development of hepatitis by inhibiting CYP2E and CYP2C, which could increase levels of other hepatotoxic drugs that are metabolized by these enzymes (eg, <a href=\"topic.htm?path=phenytoin-drug-information\" class=\"drug drug_general\">phenytoin</a> and <a href=\"topic.htm?path=carbamazepine-drug-information\" class=\"drug drug_general\">carbamazepine</a>) [<a href=\"https://www.uptodate.com/contents/isoniazid-hepatotoxicity/abstract/3\" class=\"abstract_t\">3</a>].</p><p><a href=\"topic.htm?path=rifampin-rifampicin-drug-information\" class=\"drug drug_general\">Rifampin</a> is seldom hepatotoxic when used alone but increases the activity of the CYP system and thereby can increase the production of toxic metabolites from INH. Toxic hepatitis is seen with the combination of INH and rifampin more frequently (5 to 8 percent) than with either drug alone [<a href=\"https://www.uptodate.com/contents/isoniazid-hepatotoxicity/abstract/79,90-92\" class=\"abstract_t\">79,90-92</a>], and hepatitis occurs sooner, mainly during the first month [<a href=\"https://www.uptodate.com/contents/isoniazid-hepatotoxicity/abstract/92\" class=\"abstract_t\">92</a>]. (See <a href=\"topic.htm?path=rifamycins-rifampin-rifabutin-rifapentine\" class=\"medical medical_review\">&quot;Rifamycins (rifampin, rifabutin, rifapentine)&quot;</a>.)</p><p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\"><span class=\"h1\">INFORMATION FOR PATIENTS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>UpToDate offers two types of patient education materials, &quot;The Basics&quot; and &quot;Beyond the Basics.&quot; The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &quot;patient info&quot; and the keyword(s) of interest.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Basics topics (see <a href=\"topic.htm?path=toxic-hepatitis-the-basics\" class=\"medical medical_basics\">&quot;Patient education: Toxic hepatitis (The Basics)&quot;</a>)</p><p/><p class=\"headingAnchor\" id=\"H2810569\"><span class=\"h1\">SUMMARY</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=isoniazid-drug-information\" class=\"drug drug_general\">Isoniazid</a> (INH) is a synthetic antibiotic that is bactericidal against replicating <em>Mycobacterium tuberculosis</em>. INH has been associated with two syndromes of hepatotoxicity: mild INH hepatotoxicity and INH hepatitis. (See <a href=\"#H1\" class=\"local\">'Introduction'</a> above.) </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Mild INH hepatotoxicity refers to hepatic injury that is typically subclinical and evidenced only by mildly elevated serum aminotransferases (usually &lt;100 international <span class=\"nowrap\">units/L)</span>. Most cases are self-limited; in general, INH therapy can be continued with careful monitoring. Typically, aminotransferase levels return to normal within several weeks after discontinuation of INH. (See <a href=\"#H2\" class=\"local\">'Mild INH hepatotoxicity'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>INH hepatitis is a more serious liver injury syndrome than mild INH hepatotoxicity; it is usually symptomatic and may be fatal. It is an idiosyncratic reaction that is not clearly related to dose or duration of therapy. Risk factors include age, alcohol use, use of concomitant hepatotoxic drugs, and prior or concurrent liver disease. (See <a href=\"#H3\" class=\"local\">'INH hepatitis'</a> above and <a href=\"#H4\" class=\"local\">'Prevalence and risk factors'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Clinical manifestations of INH hepatitis typically occur within the first two to three months after initiation of therapy; they include fatigue, malaise, anorexia, <span class=\"nowrap\">and/or</span> nausea, with or without vomiting. Approximately one-third of patients have generalized flu-like symptoms, and some have right upper quadrant pain. Jaundice is a presenting feature in approximately 10 percent of cases and manifests days to weeks after onset of the above symptoms. (See <a href=\"#H5\" class=\"local\">'Clinical manifestations'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The diagnosis of INH hepatitis should be suspected in patients taking INH who develop fatigue, malaise, anorexia, nausea, <span class=\"nowrap\">and/or</span> vomiting in association with elevated serum aminotransferases. The diagnosis is established clinically, based on clinical manifestations and exclusion of other causes; the diagnosis is supported by resolution of elevated aminotransferases within several weeks after discontinuation of therapy. (See <a href=\"#H6\" class=\"local\">'Diagnosis'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Clinical evaluation of patients with suspected INH hepatitis should include clinical history regarding alcohol use and exposure to other potential hepatotoxins. Laboratory evaluation should include testing for viral hepatitis and autoimmune hepatitis. (See <a href=\"#H12496295\" class=\"local\">'Differential diagnosis'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Management of INH hepatitis consists of timely discontinuation of INH and other potential hepatotoxins. In general, hepatitis attributed to antituberculous drugs should prompt discontinuation of all hepatotoxic drugs if the serum bilirubin is &ge;3 <span class=\"nowrap\">mg/dL</span> or serum transaminases are more than five times the upper limit of normal (<a href=\"image.htm?imageKey=ID%2F109447\" class=\"graphic graphic_algorithm graphicRef109447 \">algorithm 1</a>). (See <a href=\"#H7\" class=\"local\">'Management'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Use of INH should be limited to appropriate clinical circumstances, and patients should be educated about the signs and symptoms of hepatic toxicity. Issues related to clinical and laboratory monitoring for patients on <a href=\"topic.htm?path=isoniazid-drug-information\" class=\"drug drug_general\">isoniazid</a> are discussed separately. (See <a href=\"topic.htm?path=treatment-of-latent-tuberculosis-infection-in-hiv-uninfected-adults#H9\" class=\"medical medical_review\">&quot;Treatment of latent tuberculosis infection in HIV-uninfected adults&quot;, section on 'Monitoring'</a> and <a href=\"topic.htm?path=treatment-of-latent-tuberculosis-infection-in-hiv-infected-adults#H7712614\" class=\"medical medical_review\">&quot;Treatment of latent tuberculosis infection in HIV-infected adults&quot;, section on 'Patient monitoring'</a> and <a href=\"topic.htm?path=antituberculous-drugs-an-overview#H2636671244\" class=\"medical medical_review\">&quot;Antituberculous drugs: An overview&quot;, section on 'Clinical and laboratory monitoring for adverse effects'</a>.)</p><p/></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li><a href=\"https://www.uptodate.com/contents/isoniazid-hepatotoxicity/abstract/1\" class=\"nounderline abstract_t\">Nahid P, Dorman SE, Alipanah N, et al. Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis. Clin Infect Dis 2016; 63:e147.</a></li><li><a href=\"https://www.uptodate.com/contents/isoniazid-hepatotoxicity/abstract/2\" class=\"nounderline abstract_t\">Lewinsohn DM, Leonard MK, LoBue PA, et al. Official American Thoracic Society/Infectious Diseases Society of America/Centers for Disease Control and Prevention Clinical Practice Guidelines: Diagnosis of Tuberculosis in Adults and Children. Clin Infect Dis 2017; 64:e1.</a></li><li><a href=\"https://www.uptodate.com/contents/isoniazid-hepatotoxicity/abstract/3\" class=\"nounderline abstract_t\">Saukkonen JJ, Cohn DL, Jasmer RM, et al. An official ATS statement: hepatotoxicity of antituberculosis therapy. Am J Respir Crit Care Med 2006; 174:935.</a></li><li><a href=\"https://www.uptodate.com/contents/isoniazid-hepatotoxicity/abstract/4\" class=\"nounderline abstract_t\">Scharer L, Smith JP. Serum transaminase elevations and other hepatic abnormalities in patients receiving isoniazid. Ann Intern Med 1969; 71:1113.</a></li><li><a href=\"https://www.uptodate.com/contents/isoniazid-hepatotoxicity/abstract/5\" class=\"nounderline abstract_t\">Mitchell JR, Long MW, Thorgeirsson UP, Jollow DJ. Acetylation rates and monthly liver function tests during one year of isoniazid preventive therapy. Chest 1975; 68:181.</a></li><li><a href=\"https://www.uptodate.com/contents/isoniazid-hepatotoxicity/abstract/6\" class=\"nounderline abstract_t\">Hayashi PH, Fontana RJ, Chalasani NP, et al. Under-reporting and Poor Adherence to Monitoring Guidelines for Severe Cases of Isoniazid Hepatotoxicity. Clin Gastroenterol Hepatol 2015; 13:1676.</a></li><li><a href=\"https://www.uptodate.com/contents/isoniazid-hepatotoxicity/abstract/7\" class=\"nounderline abstract_t\">Mitchell JR, Zimmerman HJ, Ishak KG, et al. Isoniazid liver injury: clinical spectrum, pathology, and probable pathogenesis. Ann Intern Med 1976; 84:181.</a></li><li><a href=\"https://www.uptodate.com/contents/isoniazid-hepatotoxicity/abstract/8\" class=\"nounderline abstract_t\">Yamada S, Tang M, Richardson K, et al. Genetic variations of NAT2 and CYP2E1 and isoniazid hepatotoxicity in a diverse population. Pharmacogenomics 2009; 10:1433.</a></li><li><a href=\"https://www.uptodate.com/contents/isoniazid-hepatotoxicity/abstract/9\" class=\"nounderline abstract_t\">P V K, Palaian S, Ojha P, P R S. Pattern of adverse drug reactions experienced by tuberculosis patients in a tertiary care teaching hospital in Western Nepal. Pak J Pharm Sci 2008; 21:51.</a></li><li><a href=\"https://www.uptodate.com/contents/isoniazid-hepatotoxicity/abstract/10\" class=\"nounderline abstract_t\">Vieira DE, Gomes M. Adverse effects of tuberculosis treatment: experience at an outpatient clinic of a teaching hospital in the city of S&atilde;o Paulo, Brazil. J Bras Pneumol 2008; 34:1049.</a></li><li><a href=\"https://www.uptodate.com/contents/isoniazid-hepatotoxicity/abstract/11\" class=\"nounderline abstract_t\">Chalasani N, Fontana RJ, Bonkovsky HL, et al. Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States. Gastroenterology 2008; 135:1924.</a></li><li><a href=\"https://www.uptodate.com/contents/isoniazid-hepatotoxicity/abstract/12\" class=\"nounderline abstract_t\">Salpeter SR. Fatal isoniazid-induced hepatitis. Its risk during chemoprophylaxis. West J Med 1993; 159:560.</a></li><li><a href=\"https://www.uptodate.com/contents/isoniazid-hepatotoxicity/abstract/13\" class=\"nounderline abstract_t\">Metushi I, Uetrecht J, Phillips E. Mechanism of isoniazid-induced hepatotoxicity: then and now. Br J Clin Pharmacol 2016; 81:1030.</a></li><li><a href=\"https://www.uptodate.com/contents/isoniazid-hepatotoxicity/abstract/14\" class=\"nounderline abstract_t\">Garibaldi RA, Drusin RE, Ferebee SH, Gregg MB. Isoniazid-associated hepatitis. Report of an outbreak. Am Rev Respir Dis 1972; 106:357.</a></li><li><a href=\"https://www.uptodate.com/contents/isoniazid-hepatotoxicity/abstract/15\" class=\"nounderline abstract_t\">Lauterburg BH, Smith CV, Todd EL, Mitchell JR. Pharmacokinetics of the toxic hydrazino metabolites formed from isoniazid in humans. J Pharmacol Exp Ther 1985; 235:566.</a></li><li><a href=\"https://www.uptodate.com/contents/isoniazid-hepatotoxicity/abstract/16\" class=\"nounderline abstract_t\">LoBue PA, Moser KS. Use of isoniazid for latent tuberculosis infection in a public health clinic. Am J Respir Crit Care Med 2003; 168:443.</a></li><li><a href=\"https://www.uptodate.com/contents/isoniazid-hepatotoxicity/abstract/17\" class=\"nounderline abstract_t\">Centers for Disease Control and Prevention (CDC). Severe isoniazid-associated liver injuries among persons being treated for latent tuberculosis infection - United States, 2004-2008. MMWR Morb Mortal Wkly Rep 2010; 59:224.</a></li><li><a href=\"https://www.uptodate.com/contents/isoniazid-hepatotoxicity/abstract/18\" class=\"nounderline abstract_t\">Chalasani N, Bonkovsky HL, Fontana R, et al. Features and Outcomes of 899 Patients With Drug-Induced Liver Injury: The DILIN Prospective Study. Gastroenterology 2015; 148:1340.</a></li><li><a href=\"https://www.uptodate.com/contents/isoniazid-hepatotoxicity/abstract/19\" class=\"nounderline abstract_t\">Stead WW, To T, Harrison RW, Abraham JH 3rd. Benefit-risk considerations in preventive treatment for tuberculosis in elderly persons. Ann Intern Med 1987; 107:843.</a></li><li><a href=\"https://www.uptodate.com/contents/isoniazid-hepatotoxicity/abstract/20\" class=\"nounderline abstract_t\">Chan CH, Or KK, Cheung W, Woo J. Adverse drug reactions and outcome of elderly patients on antituberculosis chemotherapy with and without rifampicin. J Med 1995; 26:43.</a></li><li><a href=\"https://www.uptodate.com/contents/isoniazid-hepatotoxicity/abstract/21\" class=\"nounderline abstract_t\">Young H, Wessolossky M, Ellis J, et al. A retrospective evaluation of completion rates, total cost, and adverse effects for treatment of latent tuberculosis infection in a public health clinic in central massachusetts. Clin Infect Dis 2009; 49:424.</a></li><li><a href=\"https://www.uptodate.com/contents/isoniazid-hepatotoxicity/abstract/22\" class=\"nounderline abstract_t\">Black M, Mitchell JR, Zimmerman HJ, et al. Isoniazid-associated hepatitis in 114 patients. Gastroenterology 1975; 69:289.</a></li><li><a href=\"https://www.uptodate.com/contents/isoniazid-hepatotoxicity/abstract/23\" class=\"nounderline abstract_t\">Gr&ouml;nhagen-Riska C, Hellstrom PE, Fr&ouml;seth B. Predisposing factors in hepatitis induced by isoniazid-rifampin treatment of tuberculosis. Am Rev Respir Dis 1978; 118:461.</a></li><li class=\"breakAll\">Centers for Disease Control and Prevention. Core curriculum on tuberculosis. What the clinician should know, 4th ed. .S. Department of Health and Human Services, Public Health Services; Atlanta, 2000.</li><li><a href=\"https://www.uptodate.com/contents/isoniazid-hepatotoxicity/abstract/25\" class=\"nounderline abstract_t\">Holdiness MR. Clinical pharmacokinetics of the antituberculosis drugs. Clin Pharmacokinet 1984; 9:511.</a></li><li><a href=\"https://www.uptodate.com/contents/isoniazid-hepatotoxicity/abstract/26\" class=\"nounderline abstract_t\">Maddrey WC. Drug-related acute and chronic hepatitis. Clin Gastroenterol 1980; 9:213.</a></li><li><a href=\"https://www.uptodate.com/contents/isoniazid-hepatotoxicity/abstract/27\" class=\"nounderline abstract_t\">Dickinson DS, Bailey WC, Hirschowitz BI, et al. Risk factors for isoniazid (NIH)-induced liver dysfunction. J Clin Gastroenterol 1981; 3:271.</a></li><li><a href=\"https://www.uptodate.com/contents/isoniazid-hepatotoxicity/abstract/28\" class=\"nounderline abstract_t\">Acocella G, Bonollo L, Garimoldi M, et al. Kinetics of rifampicin and isoniazid administered alone and in combination to normal subjects and patients with liver disease. Gut 1972; 13:47.</a></li><li><a href=\"https://www.uptodate.com/contents/isoniazid-hepatotoxicity/abstract/29\" class=\"nounderline abstract_t\">Snider DE Jr, Caras GJ. Isoniazid-associated hepatitis deaths: a review of available information. Am Rev Respir Dis 1992; 145:494.</a></li><li><a href=\"https://www.uptodate.com/contents/isoniazid-hepatotoxicity/abstract/30\" class=\"nounderline abstract_t\">Ungo JR, Jones D, Ashkin D, et al. Antituberculosis drug-induced hepatotoxicity. The role of hepatitis C virus and the human immunodeficiency virus. Am J Respir Crit Care Med 1998; 157:1871.</a></li><li><a href=\"https://www.uptodate.com/contents/isoniazid-hepatotoxicity/abstract/31\" class=\"nounderline abstract_t\">Targeted tuberculin testing and treatment of latent tuberculosis infection. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, July 1999. This is a Joint Statement of the American Thoracic Society (ATS) and the Centers for Disease Control and Prevention (CDC). This statement was endorsed by the Council of the Infectious Diseases Society of America. (IDSA), September 1999, and the sections of this statement. Am J Respir Crit Care Med 2000; 161:S221.</a></li><li><a href=\"https://www.uptodate.com/contents/isoniazid-hepatotoxicity/abstract/32\" class=\"nounderline abstract_t\">Nolan CM, Goldberg SV, Buskin SE. Hepatotoxicity associated with isoniazid preventive therapy: a 7-year survey from a public health tuberculosis clinic. JAMA 1999; 281:1014.</a></li><li class=\"breakAll\">Liver Tox: Isoniazid. http://livertox.nlm.nih.gov/isoniazid.htm (Accessed on February 07, 2017).</li><li><a href=\"https://www.uptodate.com/contents/isoniazid-hepatotoxicity/abstract/34\" class=\"nounderline abstract_t\">Mach J, Huizer-Pajkos A, Mitchell SJ, et al. The effect of ageing on isoniazid pharmacokinetics and hepatotoxicity in Fischer 344 rats. Fundam Clin Pharmacol 2016; 30:23.</a></li><li><a href=\"https://www.uptodate.com/contents/isoniazid-hepatotoxicity/abstract/35\" class=\"nounderline abstract_t\">Pande JN, Singh SP, Khilnani GC, et al. Risk factors for hepatotoxicity from antituberculosis drugs: a case-control study. Thorax 1996; 51:132.</a></li><li><a href=\"https://www.uptodate.com/contents/isoniazid-hepatotoxicity/abstract/36\" class=\"nounderline abstract_t\">Durand F, Jebrak G, Pessayre D, et al. Hepatotoxicity of antitubercular treatments. Rationale for monitoring liver status. Drug Saf 1996; 15:394.</a></li><li><a href=\"https://www.uptodate.com/contents/isoniazid-hepatotoxicity/abstract/37\" class=\"nounderline abstract_t\">Saukkonen J. Challenges in reintroducing tuberculosis medications after hepatotoxicity. Clin Infect Dis 2010; 50:840.</a></li><li><a href=\"https://www.uptodate.com/contents/isoniazid-hepatotoxicity/abstract/38\" class=\"nounderline abstract_t\">Fern&aacute;ndez-Villar A, Sope&ntilde;a B, V&aacute;zquez R, et al. Isoniazid hepatotoxicity among drug users: the role of hepatitis C. Clin Infect Dis 2003; 36:293.</a></li><li><a href=\"https://www.uptodate.com/contents/isoniazid-hepatotoxicity/abstract/39\" class=\"nounderline abstract_t\">Patel PA, Voigt MD. Prevalence and interaction of hepatitis B and latent tuberculosis in Vietnamese immigrants to the United States. Am J Gastroenterol 2002; 97:1198.</a></li><li><a href=\"https://www.uptodate.com/contents/isoniazid-hepatotoxicity/abstract/40\" class=\"nounderline abstract_t\">Yew WW. Risk factors for hepatotoxicity during anti-tuberculosis chemotherapy in Asian populations. Int J Tuberc Lung Dis 2001; 5:99.</a></li><li><a href=\"https://www.uptodate.com/contents/isoniazid-hepatotoxicity/abstract/41\" class=\"nounderline abstract_t\">Chang KC, Leung CC, Yew WW, et al. Hepatotoxicity of pyrazinamide: cohort and case-control analyses. Am J Respir Crit Care Med 2008; 177:1391.</a></li><li><a href=\"https://www.uptodate.com/contents/isoniazid-hepatotoxicity/abstract/42\" class=\"nounderline abstract_t\">Bliven EE, Podewils LJ. The role of chronic hepatitis in isoniazid hepatotoxicity during treatment for latent tuberculosis infection. Int J Tuberc Lung Dis 2009; 13:1054.</a></li><li><a href=\"https://www.uptodate.com/contents/isoniazid-hepatotoxicity/abstract/43\" class=\"nounderline abstract_t\">Wu JC, Lee SD, Yeh PF, et al. Isoniazid-rifampin-induced hepatitis in hepatitis B carriers. Gastroenterology 1990; 98:502.</a></li><li><a href=\"https://www.uptodate.com/contents/isoniazid-hepatotoxicity/abstract/44\" class=\"nounderline abstract_t\">Shu CC, Lee CH, Lee MC, et al. Hepatotoxicity due to first-line anti-tuberculosis drugs: a five-year experience in a Taiwan medical centre. Int J Tuberc Lung Dis 2013; 17:934.</a></li><li><a href=\"https://www.uptodate.com/contents/isoniazid-hepatotoxicity/abstract/45\" class=\"nounderline abstract_t\">Mitchell JR, Thorgeirsson UP, Black M, et al. Increased incidence of isoniazid hepatitis in rapid acetylators: possible relation to hydranize metabolites. Clin Pharmacol Ther 1975; 18:70.</a></li><li><a href=\"https://www.uptodate.com/contents/isoniazid-hepatotoxicity/abstract/46\" class=\"nounderline abstract_t\">Bose PD, Sarma MP, Medhi S, et al. Role of polymorphic N-acetyl transferase2 and cytochrome P4502E1 gene in antituberculosis treatment-induced hepatitis. J Gastroenterol Hepatol 2011; 26:312.</a></li><li><a href=\"https://www.uptodate.com/contents/isoniazid-hepatotoxicity/abstract/47\" class=\"nounderline abstract_t\">Xiang Y, Ma L, Wu W, et al. The incidence of liver injury in Uyghur patients treated for TB in Xinjiang Uyghur autonomous region, China, and its association with hepatic enzyme polymorphisms nat2, cyp2e1, gstm1 and gstt1. PLoS One 2014; 9:e85905.</a></li><li><a href=\"https://www.uptodate.com/contents/isoniazid-hepatotoxicity/abstract/48\" class=\"nounderline abstract_t\">Seng KY, Hee KH, Soon GH, et al. Population pharmacokinetic analysis of isoniazid, acetylisoniazid, and isonicotinic acid in healthy volunteers. Antimicrob Agents Chemother 2015; 59:6791.</a></li><li><a href=\"https://www.uptodate.com/contents/isoniazid-hepatotoxicity/abstract/49\" class=\"nounderline abstract_t\">Maddrey WC, Boitnott JK. Isoniazid hepatitis. Ann Intern Med 1973; 79:1.</a></li><li><a href=\"https://www.uptodate.com/contents/isoniazid-hepatotoxicity/abstract/50\" class=\"nounderline abstract_t\">Reddy KR, Schiff ER. Hepatotoxicity of antimicrobial, antifungal, and antiparasitic agents. Gastroenterol Clin North Am 1995; 24:923.</a></li><li><a href=\"https://www.uptodate.com/contents/isoniazid-hepatotoxicity/abstract/51\" class=\"nounderline abstract_t\">Farrell FJ, Keeffe EB, Man KM, et al. Treatment of hepatic failure secondary to isoniazid hepatitis with liver transplantation. Dig Dis Sci 1994; 39:2255.</a></li><li><a href=\"https://www.uptodate.com/contents/isoniazid-hepatotoxicity/abstract/52\" class=\"nounderline abstract_t\">Israel HL, Gottlieb JE, Maddrey WC. Perspective: preventive isoniazid therapy and the liver. Chest 1992; 101:1298.</a></li><li><a href=\"https://www.uptodate.com/contents/isoniazid-hepatotoxicity/abstract/53\" class=\"nounderline abstract_t\">Girling DJ. The hepatic toxicity of antituberculosis regimens containing isoniazid, rifampicin and pyrazinamide. Tubercle 1978; 59:13.</a></li><li><a href=\"https://www.uptodate.com/contents/isoniazid-hepatotoxicity/abstract/54\" class=\"nounderline abstract_t\">Bailey WC, Weill H, DeRouen TA, et al. The effect of isoniazid on transaminase levels. Ann Intern Med 1974; 81:200.</a></li><li><a href=\"https://www.uptodate.com/contents/isoniazid-hepatotoxicity/abstract/55\" class=\"nounderline abstract_t\">Millard PS, Wilcosky TC, Reade-Christopher SJ, Weber DJ. Isoniazid-related fatal hepatitis. West J Med 1996; 164:486.</a></li><li><a href=\"https://www.uptodate.com/contents/isoniazid-hepatotoxicity/abstract/56\" class=\"nounderline abstract_t\">Levin ML, Moodie AS. Isoniazid prophylaxis and deaths in Baltimore, Maryland 1972. Bull Int Union Tuberc 1976; 51:213.</a></li><li><a href=\"https://www.uptodate.com/contents/isoniazid-hepatotoxicity/abstract/57\" class=\"nounderline abstract_t\">Long MW, Snider DE Jr, Farer LS. U.S. Public Health Service Cooperative trial of three rifampin-isoniazid regimens in treatment of pulmonary tuberculosis. Am Rev Respir Dis 1979; 119:879.</a></li><li><a href=\"https://www.uptodate.com/contents/isoniazid-hepatotoxicity/abstract/58\" class=\"nounderline abstract_t\">Wang P, Pradhan K, Zhong XB, Ma X. Isoniazid metabolism and hepatotoxicity. Acta Pharm Sin B 2016; 6:384.</a></li><li><a href=\"https://www.uptodate.com/contents/isoniazid-hepatotoxicity/abstract/59\" class=\"nounderline abstract_t\">Metushi IG, Nakagawa T, Uetrecht J. Direct oxidation and covalent binding of isoniazid to rodent liver and human hepatic microsomes: humans are more like mice than rats. Chem Res Toxicol 2012; 25:2567.</a></li><li><a href=\"https://www.uptodate.com/contents/isoniazid-hepatotoxicity/abstract/60\" class=\"nounderline abstract_t\">Chowdhury A, Santra A, Bhattacharjee K, et al. Mitochondrial oxidative stress and permeability transition in isoniazid and rifampicin induced liver injury in mice. J Hepatol 2006; 45:117.</a></li><li><a href=\"https://www.uptodate.com/contents/isoniazid-hepatotoxicity/abstract/61\" class=\"nounderline abstract_t\">Metushi IG, Sanders C, Acute Liver Study Group, et al. Detection of anti-isoniazid and anti-cytochrome P450 antibodies in patients with isoniazid-induced liver failure. Hepatology 2014; 59:1084.</a></li><li><a href=\"https://www.uptodate.com/contents/isoniazid-hepatotoxicity/abstract/62\" class=\"nounderline abstract_t\">Weber WW, Hein DW. Clinical pharmacokinetics of isoniazid. Clin Pharmacokinet 1979; 4:401.</a></li><li><a href=\"https://www.uptodate.com/contents/isoniazid-hepatotoxicity/abstract/63\" class=\"nounderline abstract_t\">Preziosi P. Isoniazid: metabolic aspects and toxicological correlates. Curr Drug Metab 2007; 8:839.</a></li><li><a href=\"https://www.uptodate.com/contents/isoniazid-hepatotoxicity/abstract/64\" class=\"nounderline abstract_t\">Boelsterli UA, Lee KK. Mechanisms of isoniazid-induced idiosyncratic liver injury: emerging role of mitochondrial stress. J Gastroenterol Hepatol 2014; 29:678.</a></li><li><a href=\"https://www.uptodate.com/contents/isoniazid-hepatotoxicity/abstract/65\" class=\"nounderline abstract_t\">Nelson SD, Mitchell JR, Timbrell JA, et al. Isoniazid and iproniazid: activation of metabolites to toxic intermediates in man and rat. Science 1976; 193:901.</a></li><li><a href=\"https://www.uptodate.com/contents/isoniazid-hepatotoxicity/abstract/66\" class=\"nounderline abstract_t\">Sarich TC, Youssefi M, Zhou T, et al. Role of hydrazine in the mechanism of isoniazid hepatotoxicity in rabbits. Arch Toxicol 1996; 70:835.</a></li><li><a href=\"https://www.uptodate.com/contents/isoniazid-hepatotoxicity/abstract/67\" class=\"nounderline abstract_t\">Timbrell JA, Mitchell JR, Snodgrass WR, Nelson SD. Isoniazid hepatoxicity: the relationship between covalent binding and metabolism in vivo. J Pharmacol Exp Ther 1980; 213:364.</a></li><li><a href=\"https://www.uptodate.com/contents/isoniazid-hepatotoxicity/abstract/68\" class=\"nounderline abstract_t\">Timbrell JA, Wright JM, Baillie TA. Monoacetylhydrazine as a metabolite of isoniazid in man. Clin Pharmacol Ther 1977; 22:602.</a></li><li><a href=\"https://www.uptodate.com/contents/isoniazid-hepatotoxicity/abstract/69\" class=\"nounderline abstract_t\">Ono Y, Noda A, Zaima Y, et al. Determination of isonicotinic acid in the presence of isoniazid and acetylisoniazid. Studies on isonicotinic acid formation from isoniazid in isolated rat hepatocytes. J Chromatogr B Biomed Appl 1996; 677:339.</a></li><li><a href=\"https://www.uptodate.com/contents/isoniazid-hepatotoxicity/abstract/70\" class=\"nounderline abstract_t\">Delaney J, Timbrell JA. Role of cytochrome P450 in hydrazine toxicity in isolated hepatocytes in vitro. Xenobiotica 1995; 25:1399.</a></li><li><a href=\"https://www.uptodate.com/contents/isoniazid-hepatotoxicity/abstract/71\" class=\"nounderline abstract_t\">Sarich TC, Adams SP, Petricca G, Wright JM. Inhibition of isoniazid-induced hepatotoxicity in rabbits by pretreatment with an amidase inhibitor. J Pharmacol Exp Ther 1999; 289:695.</a></li><li><a href=\"https://www.uptodate.com/contents/isoniazid-hepatotoxicity/abstract/72\" class=\"nounderline abstract_t\">Vuilleumier N, Rossier MF, Chiappe A, et al. CYP2E1 genotype and isoniazid-induced hepatotoxicity in patients treated for latent tuberculosis. Eur J Clin Pharmacol 2006; 62:423.</a></li><li><a href=\"https://www.uptodate.com/contents/isoniazid-hepatotoxicity/abstract/73\" class=\"nounderline abstract_t\">Parkin DP, Vandenplas S, Botha FJ, et al. Trimodality of isoniazid elimination: phenotype and genotype in patients with tuberculosis. Am J Respir Crit Care Med 1997; 155:1717.</a></li><li><a href=\"https://www.uptodate.com/contents/isoniazid-hepatotoxicity/abstract/74\" class=\"nounderline abstract_t\">Hein DW, Doll MA, Fretland AJ, et al. Molecular genetics and epidemiology of the NAT1 and NAT2 acetylation polymorphisms. Cancer Epidemiol Biomarkers Prev 2000; 9:29.</a></li><li><a href=\"https://www.uptodate.com/contents/isoniazid-hepatotoxicity/abstract/75\" class=\"nounderline abstract_t\">Cordes H, Thiel C, Aschmann HE, et al. A Physiologically Based Pharmacokinetic Model of Isoniazid and Its Application in Individualizing Tuberculosis Chemotherapy. Antimicrob Agents Chemother 2016; 60:6134.</a></li><li><a href=\"https://www.uptodate.com/contents/isoniazid-hepatotoxicity/abstract/76\" class=\"nounderline abstract_t\">Sim E, Abuhammad A, Ryan A. Arylamine N-acetyltransferases: from drug metabolism and pharmacogenetics to drug discovery. Br J Pharmacol 2014; 171:2705.</a></li><li><a href=\"https://www.uptodate.com/contents/isoniazid-hepatotoxicity/abstract/77\" class=\"nounderline abstract_t\">Walker K, Ginsberg G, Hattis D, et al. Genetic polymorphism in N-Acetyltransferase (NAT): Population distribution of NAT1 and NAT2 activity. J Toxicol Environ Health B Crit Rev 2009; 12:440.</a></li><li><a href=\"https://www.uptodate.com/contents/isoniazid-hepatotoxicity/abstract/78\" class=\"nounderline abstract_t\">Ellard GA, Mitchison DA, Girling DJ, et al. The hepatic toxicity of isoniazid among rapid and slow acetylators of the drug. Am Rev Respir Dis 1978; 118:628.</a></li><li><a href=\"https://www.uptodate.com/contents/isoniazid-hepatotoxicity/abstract/79\" class=\"nounderline abstract_t\">Pessayre D, Larrey D. Acute and chronic drug-induced hepatitis. Baillieres Clin Gastroenterol 1988; 2:385.</a></li><li><a href=\"https://www.uptodate.com/contents/isoniazid-hepatotoxicity/abstract/80\" class=\"nounderline abstract_t\">Yamamoto T, Suou T, Hirayama C. Elevated serum aminotransferase induced by isoniazid in relation to isoniazid acetylator phenotype. Hepatology 1986; 6:295.</a></li><li><a href=\"https://www.uptodate.com/contents/isoniazid-hepatotoxicity/abstract/81\" class=\"nounderline abstract_t\">Gurumurthy P, Krishnamurthy MS, Nazareth O, et al. Lack of relationship between hepatic toxicity and acetylator phenotype in three thousand South Indian patients during treatment with isoniazid for tuberculosis. Am Rev Respir Dis 1984; 129:58.</a></li><li><a href=\"https://www.uptodate.com/contents/isoniazid-hepatotoxicity/abstract/82\" class=\"nounderline abstract_t\">Huang YS, Chern HD, Su WJ, et al. Polymorphism of the N-acetyltransferase 2 gene as a susceptibility risk factor for antituberculosis drug-induced hepatitis. Hepatology 2002; 35:883.</a></li><li><a href=\"https://www.uptodate.com/contents/isoniazid-hepatotoxicity/abstract/83\" class=\"nounderline abstract_t\">Huang YS, Chern HD, Su WJ, et al. Cytochrome P450 2E1 genotype and the susceptibility to antituberculosis drug-induced hepatitis. Hepatology 2003; 37:924.</a></li><li><a href=\"https://www.uptodate.com/contents/isoniazid-hepatotoxicity/abstract/84\" class=\"nounderline abstract_t\">Furet Y, Bechtel Y, Le Guellec C, et al. [Clinical relevance of N-acetyltransferase type 2 (NAT2) genetic polymorphism]. Therapie 2002; 57:427.</a></li><li><a href=\"https://www.uptodate.com/contents/isoniazid-hepatotoxicity/abstract/85\" class=\"nounderline abstract_t\">Huang YS. Genetic polymorphisms of drug-metabolizing enzymes and the susceptibility to antituberculosis drug-induced liver injury. Expert Opin Drug Metab Toxicol 2007; 3:1.</a></li><li><a href=\"https://www.uptodate.com/contents/isoniazid-hepatotoxicity/abstract/86\" class=\"nounderline abstract_t\">Cai Y, Yi J, Zhou C, Shen X. Pharmacogenetic study of drug-metabolising enzyme polymorphisms on the risk of anti-tuberculosis drug-induced liver injury: a meta-analysis. PLoS One 2012; 7:e47769.</a></li><li><a href=\"https://www.uptodate.com/contents/isoniazid-hepatotoxicity/abstract/87\" class=\"nounderline abstract_t\">Huang YS. Recent progress in genetic variation and risk of antituberculosis drug-induced liver injury. J Chin Med Assoc 2014; 77:169.</a></li><li><a href=\"https://www.uptodate.com/contents/isoniazid-hepatotoxicity/abstract/88\" class=\"nounderline abstract_t\">Ng CS, Hasnat A, Al Maruf A, et al. N-acetyltransferase 2 (NAT2) genotype as a risk factor for development of drug-induced liver injury relating to antituberculosis drug treatment in a mixed-ethnicity patient group. Eur J Clin Pharmacol 2014; 70:1079.</a></li><li><a href=\"https://www.uptodate.com/contents/isoniazid-hepatotoxicity/abstract/89\" class=\"nounderline abstract_t\">Teixeira RL, Morato RG, Cabello PH, et al. Genetic polymorphisms of NAT2, CYP2E1 and GST enzymes and the occurrence of antituberculosis drug-induced hepatitis in Brazilian TB patients. Mem Inst Oswaldo Cruz 2011; 106:716.</a></li><li><a href=\"https://www.uptodate.com/contents/isoniazid-hepatotoxicity/abstract/90\" class=\"nounderline abstract_t\">Steele MA, Burk RF, DesPrez RM. Toxic hepatitis with isoniazid and rifampin. A meta-analysis. Chest 1991; 99:465.</a></li><li><a href=\"https://www.uptodate.com/contents/isoniazid-hepatotoxicity/abstract/91\" class=\"nounderline abstract_t\">Lees AW, Allan GW, Smith J, et al. Toxicity form rifampicin plus isoniazid and rifampicin plus ethambutol therapy. Tubercle 1971; 52:182.</a></li><li><a href=\"https://www.uptodate.com/contents/isoniazid-hepatotoxicity/abstract/92\" class=\"nounderline abstract_t\">Emerit J, Decroix G, Chomette C, et al. Donn&eacute;es nouvelles sur les h&eacute;pitites observ&eacute;es au cours des traitements antituberculeux incluant la rifampicine. Revue Fran&ccedil;ais des Maladies Respiratoires 1974; 2:565.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 477 Version 19.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H2810569\"><span>SUMMARY</span></a></li><li><a href=\"#H1\" id=\"outline-link-H1\">INTRODUCTION</a></li><li><a href=\"#H2\" id=\"outline-link-H2\">MILD INH HEPATOTOXICITY</a></li><li><a href=\"#H3\" id=\"outline-link-H3\">INH HEPATITIS</a><ul><li><a href=\"#H4\" id=\"outline-link-H4\">Prevalence and risk factors</a></li><li><a href=\"#H5\" id=\"outline-link-H5\">Clinical manifestations</a></li><li><a href=\"#H6\" id=\"outline-link-H6\">Diagnosis</a></li><li><a href=\"#H12496295\" id=\"outline-link-H12496295\">Differential diagnosis</a></li><li><a href=\"#H7\" id=\"outline-link-H7\">Management</a></li><li><a href=\"#H883838081\" id=\"outline-link-H883838081\">Prevention</a></li><li><a href=\"#H10\" id=\"outline-link-H10\">Prognosis</a></li></ul></li><li><a href=\"#H11\" id=\"outline-link-H11\">MECHANISM OF HEPATOTOXICITY</a></li><li><a href=\"#PATIENT_INFORMATION\" id=\"outline-link-H3816607\">INFORMATION FOR PATIENTS</a></li><li><a href=\"#H2810569\" id=\"outline-link-H2810569\">SUMMARY</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"ID/477|ALG\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"ALGORITHMS\">ALGORITHMS</a></div><ul><li><a href=\"image.htm?imageKey=ID/109447\" class=\"graphic graphic_algorithm\">- Hepatotoxicity caused by first-line anti-TB drugs in adults</a></li></ul></li><li><div id=\"ID/477|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=CARD/76992\" class=\"graphic graphic_table\">- Cytochrome P450 3A4 (CYP3A4) inhibitors and inducers</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=antituberculous-drugs-an-overview\" class=\"medical medical_review\">Antituberculous drugs: An overview</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=approach-to-the-patient-with-abnormal-liver-biochemical-and-function-tests\" class=\"medical medical_review\">Approach to the patient with abnormal liver biochemical and function tests</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=autoimmune-hepatitis-clinical-manifestations-and-diagnosis\" class=\"medical medical_review\">Autoimmune hepatitis: Clinical manifestations and diagnosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=drug-induced-liver-injury\" class=\"medical medical_review\">Drug-induced liver injury</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=ischemic-hepatitis-hepatic-infarction-and-ischemic-cholangiopathy\" class=\"medical medical_review\">Ischemic hepatitis, hepatic infarction, and ischemic cholangiopathy</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=toxic-hepatitis-the-basics\" class=\"medical medical_basics\">Patient education: Toxic hepatitis (The Basics)</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=rifamycins-rifampin-rifabutin-rifapentine\" class=\"medical medical_review\">Rifamycins (rifampin, rifabutin, rifapentine)</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=treatment-of-drug-susceptible-pulmonary-tuberculosis-in-hiv-uninfected-adults\" class=\"medical medical_review\">Treatment of drug-susceptible pulmonary tuberculosis in HIV-uninfected adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=treatment-of-latent-tuberculosis-infection-in-hiv-infected-adults\" class=\"medical medical_review\">Treatment of latent tuberculosis infection in HIV-infected adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=treatment-of-latent-tuberculosis-infection-in-hiv-uninfected-adults\" class=\"medical medical_review\">Treatment of latent tuberculosis infection in HIV-uninfected adults</a></li></ul></div></div>","javascript":null}